John De Koning

John de Koning, Ph.D. is a partner at LSP (Life Sciences Partners), one of Europe’s leading investors in the healthcare sector. In addition to Aelin Therapeutics, John currently serves on the boards of Merus (NASDAQ: MRUS), GTX medical and eTheRNA. He also served on the boards of several other companies, such as argenx (NASDAQ: ARGX), BMEYE (acquired by Edwards Lifesciences) and Prosensa (acquired by BioMarin). Prior to joining LSP in 2006, John was the Managing Director of Semaia Pharmaceuticals (acquired by Hybrigenics). Previously, he was a senior researcher within several prestigious medical research labs and worked with, among others, Prof. Hans Clevers, Prof. Bob Löwenberg and Prof. Allan Balmain. John has a Master’s degree in Medical Biology from the University of Utrecht and a Ph.D. in Oncology from the Erasmus University Rotterdam, both in the Netherlands. After obtaining his Ph.D., he received a prestigious fellowship from the Dutch Cancer Society to work at the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco. His results were published in numerous leading scientific journals, including Nature Genetics.